Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

Jaffer A. Ajani, James L. Abbruzzese, Avi Markowitz, Yehuda Z. Patt, Karen Daugherty

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

    Original languageEnglish (US)
    Pages (from-to)67-69
    Number of pages3
    JournalInvestigational New Drugs
    Volume11
    Issue number1
    DOIs
    StatePublished - Feb 1993

    Fingerprint

    Etoposide
    Interferon-alpha
    Colorectal Neoplasms

    Keywords

    • alpha-interferon
    • colorectal carcinoma
    • etoposide

    ASJC Scopus subject areas

    • Pharmacology
    • Molecular Medicine

    Cite this

    Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. / Ajani, Jaffer A.; Abbruzzese, James L.; Markowitz, Avi; Patt, Yehuda Z.; Daugherty, Karen.

    In: Investigational New Drugs, Vol. 11, No. 1, 02.1993, p. 67-69.

    Research output: Contribution to journalArticle

    Ajani, Jaffer A. ; Abbruzzese, James L. ; Markowitz, Avi ; Patt, Yehuda Z. ; Daugherty, Karen. / Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. In: Investigational New Drugs. 1993 ; Vol. 11, No. 1. pp. 67-69.
    @article{839f75371d774f35900faff2ead3369b,
    title = "Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma",
    abstract = "Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.",
    keywords = "alpha-interferon, colorectal carcinoma, etoposide",
    author = "Ajani, {Jaffer A.} and Abbruzzese, {James L.} and Avi Markowitz and Patt, {Yehuda Z.} and Karen Daugherty",
    year = "1993",
    month = "2",
    doi = "10.1007/BF00873914",
    language = "English (US)",
    volume = "11",
    pages = "67--69",
    journal = "Investigational New Drugs",
    issn = "0167-6997",
    publisher = "Kluwer Academic Publishers",
    number = "1",

    }

    TY - JOUR

    T1 - Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma

    AU - Ajani, Jaffer A.

    AU - Abbruzzese, James L.

    AU - Markowitz, Avi

    AU - Patt, Yehuda Z.

    AU - Daugherty, Karen

    PY - 1993/2

    Y1 - 1993/2

    N2 - Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

    AB - Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

    KW - alpha-interferon

    KW - colorectal carcinoma

    KW - etoposide

    UR - http://www.scopus.com/inward/record.url?scp=0027195834&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0027195834&partnerID=8YFLogxK

    U2 - 10.1007/BF00873914

    DO - 10.1007/BF00873914

    M3 - Article

    VL - 11

    SP - 67

    EP - 69

    JO - Investigational New Drugs

    JF - Investigational New Drugs

    SN - 0167-6997

    IS - 1

    ER -